fashion -WSS

fashion

author：Wikipedia 2025-09-02 08:14:16 - browse：8949

SAN DIEGO — One of the toughest subtypes of acute leukemia involves a genetic alteration in the KMT2A gene. Many cancers with this genetic alteration end up relapsing or don’t respond to treatment, but new data presented at the annual American Society of Hematology meeting offer hope of a new targeted therapy for these patients.

The study, called the Phase 2 Augment-101 trial, tested Syndax’s revumenib in patients with relapsed or refractory leukemia with these KMT2A genetic rearrangements. Overall, about 63% of the patients responded to the treatment, with many able to receive a potentially curative stem cell transplant later on, which is often the ultimate goal for patients with relapsed or refractory patients, said Ibrahim Aldoss, a hematologist-oncologist at City of Hope and the study’s presenter, in an interview.

“KMT2A-rearranged diseases represent 10% of all leukemia. They can be exceptionally hard to treat,” Aldoss said. “The median overall survival remains low with current available treatment. Right now there’s no targeted therapy for KMT2A-rearranged disease. We’re really excited about revumenib as it targets the mutation, and we’re seeing encouraging outcomes.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Printout prescription drug information shouldn’t go digital

focus

WSS

An Ebola outbreak presents a new mystery involving children

FDA sets aggressive timeline for overhauling inspection procedures

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

FDA sets aggressive timeline for overhauling inspection procedures

An Ebola outbreak presents a new mystery involving children

Cardiologists urge adding sexual orientation, gender identity to health records

leisure time

fashion

Wikipedia

After affirmative action ruling, medical educators look to 'holistic review'

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Zapping the brain for stroke rehab: Pivotal clinical trial begins

Medical records are filled with copy

The painfully weak evidence on taking collagen to treat arthritis

As demand for Covid shots wanes, Moderna seeks its next success

CDC launches VaccineFinder tool to locate Covid

Sports medicine is finally prioritizing gender equality

An Ebola outbreak presents a new mystery involving children

entertainment

Mass General, Mayo Clinic look to monetize custom

Choosing scientific sides in the fight against Alzheimer's

‘The Bear’ and hospitality in hospitals

The painfully weak evidence on taking collagen to treat arthritis

High breast density mammograms need follow

Discs beat pads, tampons for heavy menstrual flow, new study shows

knowledge

hotspot

focus

focus